Universiteit Maastricht
- Address
- lock Available on a paid plan
Neoplasms and pulmonary oncology
At Universiteit Maastricht, research in neoplasms focuses on non-small cell lung cancer, with clinical trials aimed at improving outcomes for people whose disease has already been treated. The work is centered on evaluating a new cancer therapy against an established treatment to better understand its impact on survival and disease control.
- Study of non-small cell lung cancer in previously treated patients
- Assessment of treatment effectiveness for overall survival and disease progression
- Research into pulmonary diseases with an oncology focus
These trials reflect the site’s interest in refining lung cancer care through evidence that can guide future treatment choices in clinical practice.
Nutritional and metabolic diseases
The Department of pulmonary diseases at Universiteit Maastricht also supports research in nutritional and metabolic diseases, particularly type 2 diabetes. One trial is exploring whether changing branched-chain amino acid metabolism can help improve glucose homeostasis and lower fasting blood sugar levels.
- Research on type 2 diabetes and blood sugar regulation
- Investigation of BCAA oxidation as a way to improve metabolic control
- Testing a new approach to support glucose-lowering strategies
This line of research aims to deepen understanding of how metabolism influences diabetes and may open the door to better diagnostic and treatment approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Universiteit Maastricht1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universiteit Maastricht
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study Comparing Sigvotatug Vedotin and Docetaxel in Adults with Previously Treated Non-Small Cell Lung Cancer | Seagen Inc. | Phase III | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Docetaxel | 1 | Unknown | 2024-02-16 | 2024-02-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.